The Year in Heart Failure

Journal of the American College of Cardiology

Volumn 52, Issue 20, 2008, Pages 1671-1678

  Tang, W H Wilson ^a   Francis, Gary S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

heart failure; transplant

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BUCINDOLOL; DIURETIC AGENT; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; NESIRITIDE; PLACEBO; RAMIPRIL; ROSUVASTATIN; SILDENAFIL;

ANEMIA; ARTIFICIAL VENTILATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC HEART FAILURE; DISEASE EXACERBATION; DRUG EFFICACY; GENE MUTATION; GENETIC COUNSELING; HEART HEMODYNAMICS; HEREDITY; HUMAN; KIDNEY PRESERVATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY;

EID: 55149118206     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.08.026     Document Type: Review

References (101)

1. Keren A., Syrris P., and McKenna W.J. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 5 (2008) 158-168
2. Morita H., Rehm H.L., Menesses A., et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 358 (2008) 1899-1908
3. Olivotto I., Girolami F., Ackerman M.J., et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 83 (2008) 630-638
4. Christiaans I., Birnie E., Bonsel G.J., Wilde A.A., and van Langen I.M. Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum Genet 16 (2008) 1201-1207
5. Hershberger R.E., Parks S.B., Kushner J.D., et al. Coding sequence mutations identified in MYH7, TNNT2, SNC5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Translational Sci 1 (2008) 21-26
6. Parks S.B., Kushner J.D., Nauman D., et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 156 (2008) 161-169
7. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14 (2008) 510-517
8. Loscalzo J. Association studies in an era of too much information: clinical analysis of new biomarker and genetic data. Circulation 116 (2007) 1866-1870
9. Sehnert A.J., Daniels S.E., and Elashoff M. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 52 (2008) 644-651
10. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
11. Heidecker B., Kasper E.K., Wittstein I.S., et al. Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation 118 (2008) 238-246
12. Cooper L.T., Baughman K.L., Feldman A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116 (2007) 2216-2233
13. Braunwald E. Biomarkers in heart failure. N Engl J Med 358 (2008) 2148-2159
14. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., and Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54 (2008) 752-756
15. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail (2008) In press
16. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
17. Rosenberg M., Zugck C., Nelles M., et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 1 (2008) 43-49
18. Neuhold S., Huelsmann M., Strunk G., et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52 (2008) 266-272
19. Hartog J.W., Voors A.A., Schalkwijk C.G., et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 28 (2007) 2879-2885
20. Tang W.H., Tong W., Shrestha K., et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J (2008) Aug 6 [E-pub ahead of print]
21. Frantz R.P., Lowes B.D., Grayburn P.A., et al. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). J Card Fail 13 (2007) 437-444
22. McMurray J.J.V., Pitt B., Latini R., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1 (2008) 17-24
23. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
24. Hare J.M., Mangal B., Brown J., et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 51 (2008) 2301-2309
25. Mant D., Hobbs F.R., Glasziou P., et al. Identification and guided treatment of ventricular dysfunction in general practice using blood B-type natriuretic peptide. Br J Gen Pract 58 (2008) 393-399
26. Cheung N., Wang J.J., Rogers S.L., et al. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 51 (2008) 1573-1578
27. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117 (2008) 2544-2565
28. Butler J., Kalogeropoulos A.P., Georgiopoulou V., et al. Incident heart failure prediction in the elderly: the Healt ABC Heart Failure Score. Circ Heart Fail 1 (2008) 125-133
29. Abraham W.T., Fonarow G.C., Albert N.M., et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 52 (2008) 347-356
30. Damman K., Navis G., Smilde T.D., et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9 (2007) 872-878
31. Gheorghiade M., Rossi J.S., Cotts W., et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 167 (2007) 1998-2005
32. Metra M., Nodari S., Parrinello G., et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 9 (2007) 776-786
33. Cauthen C.A., Lipinski M.J., Abbate A., et al. Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol 101 (2008) 1643-1647
34. Klein L., Massie B.M., Leimberger J.D., et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous ilrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 1 (2008) 25-33
35. Lassus J., Harjola V.P., Sund R., et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28 (2007) 1841-1847
36. Tang W.H., Van Lente F., Shrestha K., et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail 14 (2008) 394-399
37. Moran A., Katz R., Smith N.L., et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 14 (2008) 19-26
38. van der Harst P., Wong L.S., de Boer R.A., et al. Possible association between telomere length and renal dysfunction in patients with chronic heart failure. Am J Cardiol 102 (2008) 207-210
39. Nohria A., Hasselblad V., Stebbins A., et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51 (2008) 1268-1274
40. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2008) In press
41. Qureshi A.S., Shapiro R.S., and Leatherman J.W. Use of bladder pressure to correct for the effect of expiratory muscle activity on central venous pressure. Intensive Care Med 33 (2007) 1907-1912
42. Mullens W., Abrahams Z., Skouri H.N., et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?. J Am Coll Cardiol 51 (2008) 300-306
43. Mullens W., Abrahams Z., Francis G.S., Taylor D.O., Starling R.C., and Tang W.H. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail 14 (2008) 508-514
44. Cleland J.G., Taylor J., and Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 357 (2007) 829-830
45. McMurray J.J., Carson P.E., Komajda M., et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 10 (2008) 149-156
46. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-2550
47. Olivotto I., Maron M.S., Autore C., et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 52 (2008) 559-566
48. Fonarow G.C., Yancy C.W., Albert N.M., et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE-HF. Circ Heart Fail 1 (2008) 98-106
49. Metra M., Torp-Pedersen C., Cleland J.G., et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure?. Results from COMET. Eur J Heart Fail 9 (2007) 901-909
50. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52 (2008) 190-199
51. Ahmed A., Young J.B., Love T.E., Levesque R., and Pitt B. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 125 (2008) 246-253
52. Mielniczuk L.M., Tsang S.W., Desai A.S., et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 14 (2008) 388-393
53. Stevenson L.W. Challenges for the basis of practice in heart failure. Circ Heart Fail 1 (2008) 81-83
54. Ramasubbu K., Estep J., White D.L., Deswal A., and Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008) 415-426
55. The GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) Aug 29 [E-pub ahead of print]
56. Yancy C.W., Krum H., Massie B., et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial. Circ Heart Fail 1 (2008) 9-16
57. Owan T.E., Chen H.H., Frantz R.P., et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail 14 (2008) 267-275
58. Witteles R.M., Kao D., Christopherson D., et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 50 (2007) 1835-1840
59. Levy P., Compton S., Welch R., et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 50 (2007) 144-152
60. Mullens W., Abrahams Z., Francis G.S., et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 52 (2008) 200-207
61. Gheorghiade M., Blair J.E., Filippatos G.S., et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51 (2008) 2276-2285
62. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., and Burnett Jr. J.C. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52 (2008) 60-68
63. Guazzi M., Samaja M., Arena R., Vicenzi M., and Guazzi M.D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50 (2007) 2136-2144
64. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555-1562
65. Yip G.W., Wang M., Wang T., et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 94 (2008) 573-580
66. Stewart R.A., Kerr A.J., Cowan B.R., et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J 156 (2008) 348-355
67. Tang W.H., Tong W., Jain A., Francis G.S., Harris C.M., and Young J.B. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 51 (2008) 569-576
68. Toblli J.E., Lombrana A., Duarte P., and Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007) 1657-1665
69. Kourea K., Parissis J.T., Farmakis D., et al. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 199 (2008) 215-221
70. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51 (2008) 103-112
71. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117 (2008) 526-535
72. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28 (2007) 2208-2216
73. Parissis J.T., Kourea K., Panou F., et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 155 (2008) 751 e1-7
74. Rogers H.L., Marshall J., Bock J., et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail 14 (2008) 1-5
75. Cleland J.G., Coletta A.P., Yassin A., et al. Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE. Eur J Heart Fail 10 (2008) 614-620
76. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008) 2667-2677
77. Boldt L.H., Rolf S., Huemer M., et al. Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Am Heart J 155 (2008) 890-895
78. Rusinaru D., Leborgne L., Peltier M., and Tribouilloy C. Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction. Eur J Heart Fail 10 (2008) 566-572
79. Carbucicchio C., Santamaria M., Trevisi N., et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 117 (2008) 462-469
80. Taieb J.M., Maury P., Shah D., et al. Reversal of dilated cardiomyopathy by the elimination of frequent left or right premature ventricular contractions. J Interv Card Electrophysiol 20 (2007) 9-13
81. Bogun F., Crawford T., Reich S., et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 4 (2007) 863-867
82. Efremidis M., Letsas K.P., Sideris A., and Kardaras F. Reversal of premature ventricular complex-induced cardiomyopathy following successful radiofrequency catheter ablation. Europace 10 (2008) 769-770
83. Beshai J.F., Grimm R.A., Nagueh S.F., et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 357 (2007) 2461-2471
84. Cleland J.G., Freemantle N., Daubert J.C., Toff W.D., Leisch F., and Tavazzi L. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart 94 (2008) 278-283
85. Landolina M., Lunati M., Gasparini M., et al. Comparison of the effects of cardiac resynchronization therapy in patients with class II versus class III and IV heart failure (from the InSync/InSync ICD Italian Registry). Am J Cardiol 100 (2007) 1007-1012
86. Richardson M., Freemantle N., Calvert M.J., Cleland J.G., and Tavazzi L. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. Eur Heart J 28 (2007) 1827-1834
87. Di Biase L., Auricchio A., Sorgente A., et al. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J (2008) May 30 [E-pub ahead of print]
88. Soliman O.I., Geleijnse M.L., Theuns D.A., et al. Reverse of left ventricular volumetric and structural remodeling in heart failure patients treated with cardiac resynchronization therapy. Am J Cardiol 101 (2008) 651-657
89. Vanderheyden M., Mullens W., Delrue L., et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 51 (2008) 129-136
90. Chung E.S., Leon A.R., Tavazzi L., et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 117 (2008) 2608-2616
91. Haft J., Armstrong W., Dyke D.B., et al. Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices. Circulation 116 (2007) I8-I15
92. Mann D.L., Acker M.A., Jessup M., Sabbah H.N., Starling R.C., and Kubo S.H. Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg 84 (2007) 1226-1235
93. Starling R.C., Jessup M., Oh J.K., et al. Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg 84 (2007) 1236-1242
94. Borggrefe M.M., Lawo T., Butter C., et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 29 (2008) 1019-1028
95. Butter C., Rastogi S., Minden H.H., Meyhofer J., Burkhoff D., and Sabbah H.N. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol 51 (2008) 1784-1789
96. Fonarow G.C., Abraham W.T., Albert N.M., et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 168 (2008) 847-854
97. Lainscak M., Cleland J.G., Lenzen M.J., et al. Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis. Eur J Heart Fail 9 (2007) 1095-1103
98. Allen L.A., Yager J.E., Funk M.J., et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 299 (2008) 2533-2542
99. Selman L., Harding R., Beynon T., et al. Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't.". Heart 93 (2007) 963-967
100. Henkel D.M., Redfield M.M., Weston S.A., Gerber Y., and Roger V.L. Death in heart failure: a community perspective. Circ Heart Fail 1 (2008) 91-97
101. Young J.B., Abraham W.T., Bourge R.C., Konstam M.A., and Stevenson L.W. Task force 8: training in heart failure endorsed by the Heart Failure Society of America. J Am Coll Cardiol 51 (2008) 383-389